Nuvectis Pharma Inc
NASDAQ:NVCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nuvectis Pharma Inc
NASDAQ:NVCT
|
US |
|
T
|
Tri Chemical Laboratories Inc
F:22E
|
JP |
|
Fomento de Construcciones y Contratas SA
F:FCC
|
ES |
Intrinsic Value
The intrinsic value of Nuvectis Pharma Inc (NVCT) under the Base Case is 1.83 USD per share.
Compared with the current market price of 18.57 USD, the stock appears
Overvalued by 90% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Nuvectis Pharma Does
Nuvectis Pharma is a clinical-stage biotechnology company focused on developing drug candidates for cancer. Its main work is to discover and test small-molecule medicines that target specific signaling pathways in tumors, with the goal of treating cancers that still have few good options.
- Headquarters
- United States of America US
- Employees
- 12
- IPO date
- Feb 4, 2022
Earnings Waterfall
Nuvectis Pharma Inc
The intrinsic value for Nuvectis Pharma Inc (NVCT) under the Base Case is 1.83 USD.
Compared with the current market price of 18.57 USD, the stock appears Overvalued by 90% .